Wednesday, October 1, 2014

Only 5 more days before the close of the BiotechInvestor.com Pick'em Contest! Chance to win $500!!!

The 4th quarter is upon us and filled with lots of biotech catalysts.  What better way to follow some of these catalysts than the BiotechInvestor.com Pick’em Contest!  All content submissions must be received by October 5th.  The winner will receive $500 and the rules are simple.

You must be signed up to receive my blog alerts, following me on Twitter, and liking my on Facebook for your submission to qualify. 
One submission per person.
All submissions must be made via the contact form at the bottom of my blog.
All submissions must include your legal name and email address to ensure prize money is sent to the correct winner. 
The person with the most correct picks wins.  If there is a tie, the prize money of $500 will be split between winners. 
Only catalysts that occur by the end of the day on December 31st, 2014 will count towards the contest results.
Submit your picks by the question numbers 1 - 15.  
This contest is meant to be fun!

1. Will the FDA approve NPS Pharma’s (NPSP) Natpara to treat hyperparathyroidism?  PDUFA date October 24th.
2. Will the FDA approve Aeterna Zentaris (AEZS) Macimorelin Acetate for Adult Growth Deficiency?  PDUFA date November 5th.
3. Will Bind Therapeutics (BIND) Phase 2 study of Bind-014 in Prostate Cancer meet its primary endpoint?
4. Will Bind Therapeutics (BIND) Phase 2 study of Bind-014 in NSLC meet its primary endpoint? 
5. Will Targacept (TRGT) find a product to in license due to their cash stockpile and lack of pipeline after recent trail failures in their lead compounds?
6. Will Vivus (VVUS) find a partner to help sell its weight loss product, Qsymia, in the United States?
7. Will Array (ARRY) Phase 2 study of ARRY-797 in LMNA-related DCM meet its primary endpoint?
8. Will the FDA approve Navidea’s (NAVB) label expansion of Lymphoseek?  PDUGA date October 16th.
9. Will Merrimack (MACK) file its NDA for MM-398 in Pancreatic Cancer by year-end?
10. Will Exelixis (EXEL) receive a buyout offer after the failure of its lead compound in Prostate cancer and the subsequent plummet of its share price?
11. Will Sunesis (SNSS) Phase 3 study of Vosaroxin in AML meet its primary endpoint?
12. Will Cyclacel complete enrollment in its Phase 3 study of Sapacitibine in AML by year-end?
13. Will Marina Biotech (MRNA) report a partnership in rare diseases leveraging its extensive RNAi intellectual property portfolio by the end of the year?
14. Will any of the following small-cap biotech’s announce a pharma partnership by the end of the year – Rigel (RIGL), Anthera (ANTH), Arqule (ARQL), Celator (CPXX), KaloBios (KBIO), or Oncogenex (OGXI)? 
15. What will Mannkind’s share price be at end of trading on December 31st, 2014?

Tuesday, September 30, 2014

Merrimack (MACK) Reports Good News

Merrimack (MACK) provided updated clinical date on its compound MM-121.  The drug initially showed a lack of statistical benefit in Phase 2 trails but the biomarker data has been analyzed and showed that the compound increased Progression Free Survival in patients with biomarker positive metatastic breast cancer by 74%.  This is encouraging news for both the company and patients and I'd expect Merrimack to provide a strategic update on a pivotal trial in this patient subgroup in the future.


BiotechInvestor.com 4th Quarter Pick’em Contest - $500 Prize!

The 4th quarter is upon us and filled with lots of biotech catalysts.  What better way to follow some of these catalysts than the BiotechInvestor.com Pick’em Contest!  All content submissions must be received by October 5th.  The winner will receive $500 and the rules are simple.

You must be signed up to receive my blog alerts, following me on Twitter, and liking my on Facebook for your submission to qualify. 
One submission per person.
All submissions must be made via the contact form at the bottom of my blog.
All submissions must include your legal name and email address to ensure prize money is sent to the correct winner. 
The person with the most correct picks wins.  If there is a tie, the prize money of $500 will be split between winners. 
Only catalysts that occur by the end of the day on December 31st, 2014 will count towards the contest results.
Submit your picks by the question numbers 1 - 15.  
This contest is meant to be fun!

1. Will the FDA approve NPS Pharma’s (NPSP) Natpara to treat hyperparathyroidism?  PDUFA date October 24th.
2. Will the FDA approve Aeterna Zentaris (AEZS) Macimorelin Acetate for Adult Growth Deficiency?  PDUFA date November 5th.
3. Will Bind Therapeutics (BIND) Phase 2 study of Bind-014 in Prostate Cancer meet its primary endpoint?
4. Will Bind Therapeutics (BIND) Phase 2 study of Bind-014 in NSLC meet its primary endpoint? 
5. Will Targacept (TRGT) find a product to in license due to their cash stockpile and lack of pipeline after recent trail failures in their lead compounds?
6. Will Vivus (VVUS) find a partner to help sell its weight loss product, Qsymia, in the United States?
7. Will Array (ARRY) Phase 2 study of ARRY-797 in LMNA-related DCM meet its primary endpoint?
8. Will the FDA approve Navidea’s (NAVB) label expansion of Lymphoseek?  PDUGA date October 16th.
9. Will Merrimack (MACK) file its NDA for MM-398 in Pancreatic Cancer by year-end?
10. Will Exelixis (EXEL) receive a buyout offer after the failure of its lead compound in Prostate cancer and the subsequent plummet of its share price?
11. Will Sunesis (SNSS) Phase 3 study of Vosaroxin in AML meet its primary endpoint?
12. Will Cyclacel complete enrollment in its Phase 3 study of Sapacitibine in AML by year-end?
13. Will Marina Biotech (MRNA) report a partnership in rare diseases leveraging its extensive RNAi intellectual property portfolio by the end of the year?
14. Will any of the following small-cap biotech’s announce a pharma partnership by the end of the year – Rigel (RIGL), Anthera (ANTH), Arqule (ARQL), Celator (CPXX), KaloBios (KBIO), or Oncogenex (OGXI)? 



15. What will Mannkind’s share price be at end of trading on December 31st, 2014?